News

Emessar Biotech & Nutrition Limited informed the Bombay Stock Exchange that the trading window for dealing in the company`s securities will be closed from October 1, 2026, until 48 hours after the financial results for the quarter ending September 30, 2026, become publicly available, in accordance with SEBI Prohibition of Insider Trading Regulations.

Net profit of Emmessar Biotech & Nutrition declined 23.53% to Rs 0.13 crore in the quarter ended June 2026 as against Rs 0.17 crore during the previous quarter ended June 2025. Sales declined 33.33% to Rs 0.06 crore in the quarter ended June 2026 as against Rs 0.09 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales0.060.09 -33 OPM %-600.00-311.11 - PBDT0.180.25 -28 PBT0.160.23 -30 NP0.130.17 -24 Powered by Capital Market - Live News

Emmessar Biotech & Nutrition will hold a meeting of the Board of Directors of the Company on 7 August 2026.

Net profit of Emmessar Biotech & Nutrition reported to Rs 0.03 crore in the quarter ended March 2026 as against net loss of Rs 0.07 crore during the previous quarter ended March 2025. Sales declined 10.00% to Rs 0.09 crore in the quarter ended March 2026 as against Rs 0.10 crore during the previous quarter ended March 2025.For the full year,net profit rose 37.50% to Rs 0.44 crore in the year ended March 2026 as against Rs 0.32 crore during the previous year ended March 2025. Sales declined 39.34% to Rs 0.37 crore in the year ended March 2026 as against Rs 0.61 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales0.090.10 -10 0.370.61 -39 OPM %-411.11-330.00 --367.57-155.74 - PBDT0.100.28 -64 0.681.06 -36 PBT0.070.26 -73 0.580.96 -40 NP0.03-0.07 LP 0.440.32 38 Powered by Capital Market - Live News

Emmessar Biotech & Nutrition will hold a meeting of the Board of Directors of the Company on 12 May 2026.